Friday, August 21, 2009

CASPPER, GlaxoSmithKline’s Friendly Ghostwriting Program





A while back I posted an item about scientific articles being "ghostwritten" by professional outfits, hired by pharmaceutical companies to author scientific articles, after which the names of well-known scientists and researchers are substituted or added as authors. Well, the issue is really heating up now.


The Chicago Tribune published an article on August 20, 2009, talking about a program called CASPPER. Funded by GlaxoSmithKline, many of the articles focus on the antidepressant drug, Paxil. Here is a link to that story.


http://www.chicagotribune.com/business/sns-ap-us-glaxosmithkline-ghostwriting,0,4281174.story


The Wall Street Journal is also in the fray:


http://blogs.wsj.com/health/2009/08/20/caspper-glaxosmithklines-friendly-ghostwriting-program/


Yesterday, The New York Times posted a similar article detailing how another company used ghostwriters to prepare scientific papers for publications in major medical journals. Check out this article:


http://www.nytimes.com/2009/08/19/health/research/19ethics.html


In academia, we would probably call this plagiarism and haul any offenders before the Student Conduct Committee. Look for more on this subject.

No comments:

Post a Comment